Robertson I G, Palmer B D, Officer M, Siegers D J, Paxton J W, Shaw G J
Department of Pharmacology and Clinical Pharmacology, University of Auckland School of Medicine, New Zealand.
Biochem Pharmacol. 1991 Oct 24;42(10):1879-84. doi: 10.1016/0006-2952(91)90585-s.
The acridine antitumor agent N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601316; acridine carboxamide) is oxidized efficiently in vitro by rat and mouse hepatic cytosolic fractions. Under these conditions the oxidase activity has an apparent Km of 11 microM towards AC. A single product is formed which has been identified as the corresponding 9(10H)-acridone carboxamide by 1H-NMR and mass spectrometry. Inhibition with menadione and amsacrine, but not allopurinol, indicates that this reaction is most likely to be catalysed by aldehyde oxidase (EC 1.2.3.1). Several AC analogues with modifications to the side chain (the N-oxide, N-monomethyl-, and amino-derivatives) are also metabolized to the equivalent acridone product but the 7-hydroxylated and 4-carboxylic acid acridine derivatives are not.
吖啶类抗肿瘤药物N-[2'-(二甲氨基)乙基]吖啶-4-甲酰胺(AC;NSC 601316;吖啶甲酰胺)在体外能被大鼠和小鼠肝脏胞质部分有效氧化。在这些条件下,氧化酶活性对AC的表观Km为11微摩尔。形成了单一产物,通过1H-NMR和质谱鉴定为相应的9(10H)-吖啶酮甲酰胺。用甲萘醌和安吖啶抑制,但别嘌呤醇不抑制,表明该反应最有可能由醛氧化酶(EC 1.2.3.1)催化。几种对侧链进行修饰的AC类似物(N-氧化物、N-单甲基-和氨基衍生物)也代谢为相应的吖啶酮产物,但7-羟基化和4-羧酸吖啶衍生物则不会。